3 Stocks Improving Performance Of The Drugs Industry
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.
All three major indices are trading up today with the
Dow Jones Industrial Average
(
^DJI
) trading up 282 points (1.6%) at 17,995 as of Monday, March 30, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,172 issues advancing vs. 821 declining with 145 unchanged.
The Drugs industry currently sits up 0.5% versus the S&P 500, which is up 1.1%. Top gainers within the industry include
(
), up 15.2%,
Teva Pharmaceutical Industries
(
), up 2.6%,
(
), up 1.4%,
(
), up 1.2% and
Valeant Pharmaceuticals International
(
), up 0.8%.
TheStreet would like to highlight 3 stocks pushing the industry higher today:
3.
(
) is one of the companies pushing the Drugs industry higher today. As of noon trading, Johnson & Johnson is up $1.37 (1.4%) to $101.71 on light volume. Thus far, 2.5 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 9.2 million shares. The stock has ranged in price between $100.76-$101.86 after having opened the day at $101.24 as compared to the previous trading day's close of $100.34.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. Johnson & Johnson has a market cap of $278.4 billion and is part of the health care sector. Shares are down 4.0% year-to-date as of the close of trading on Friday. Currently there are 9 analysts who rate Johnson & Johnson a buy, no analysts rate it a sell, and 7 rate it a hold.
TheStreet Ratings rates
Johnson & Johnson
as a
. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full
Johnson & Johnson Ratings Report
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
2. As of noon trading,
(
) is up $2.04 (0.7%) to $305.60 on light volume. Thus far, 1.2 million shares of Actavis exchanged hands as compared to its average daily volume of 3.2 million shares. The stock has ranged in price between $304.86-$307.82 after having opened the day at $307.34 as compared to the previous trading day's close of $303.56.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Actavis plc develops, manufactures, and sells generic, brand, and biosimilar pharmaceuticals. It offers over-the-counter products. The company also provides biosimilar products in women's health, oncology, and other therapeutic categories. Actavis has a market cap of $80.2 billion and is part of the health care sector. Shares are up 17.9% year-to-date as of the close of trading on Friday. Currently there are 17 analysts who rate Actavis a buy, no analysts rate it a sell, and 1 rates it a hold.
TheStreet Ratings rates
Actavis
as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
1. As of noon trading,
(
) is up $0.46 (1.3%) to $34.99 on light volume. Thus far, 10.8 million shares of Pfizer exchanged hands as compared to its average daily volume of 29.9 million shares. The stock has ranged in price between $34.55-$34.99 after having opened the day at $34.61 as compared to the previous trading day's close of $34.53.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Pfizer has a market cap of $209.8 billion and is part of the health care sector. Shares are up 10.8% year-to-date as of the close of trading on Friday. Currently there are 9 analysts who rate Pfizer a buy, 1 analyst rates it a sell, and 4 rate it a hold.
TheStreet Ratings rates
Pfizer
as a
. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
null